Syngene to acquire Baltimore-Bayview facility from Emergent BioSolutions for $36.5m.

Syngene International, a company specializing in contract pharmaceutical services, agreed to acquire Baltimore-Bayview facility from Emergent BioSolutions, a drug substance manufacturing facility, for $36.5m. "The sale of Bayview represents a continuation of our efforts to deliver on our multi-year transformation plan and creates a streamlined, customer-focused, leaner, more flexible organization that provides the capabilities to deliver our product demand today and into the future," Joe Papa, Emergent BioSolutions President and CEO.